Press release: Umeå, 18 March 2021. Lipum's final report for the EU's Horizon 2020 framework program has been approved and the company will receive 496,000 EUR as final payment from the program.
Horizon 2020, the EU's framework program for research and development, has granted Lipum a total of EUR 2.2 million to develop SOL-116 for treatment of chronic inflammatory diseases.
"The contribution from Horizon 2020 has been central and giving us the opportunity to develop the drug candidate SOL-116. This has a new mechanism of action and potential to be the first in a new drug class for treatment of chronic inflammatory diseases" says CEO Einar Pontén.
SOL-116 is a therapeutic antibody where the primary focus is on treatment of rheumatism in adults and children. Preparations are underway to start clinical trials in 2022.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 5783495
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.